Studies on the host related factors determining clinical manifestation of the Helicobacter pylori infection among patients with various ethnic backgrounds.

不同种族背景患者幽门螺杆菌感染临床表现的宿主相关因素研究

• 批准号: 11691206
• 负责人: WAKATSUKI Yoshio
• 金额: $ 4.74万
• 依托单位: KYOTO UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2001
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-11691206/
• 关键词: H.pylori; Immunology; Mucosal immunology; epidemiology; Pathology; Gastroenterology

Huge population in the world, more than two billions, and more than sixty millions of people in Japan are infected with Helicobacter pylori (H.pylori). Huge sum of money is also invested for the treatment as well as prevention of the diseases related to H.pylori infection. Not all of the patients with this infection develop such diseases as peptic ulcers, MALTOMAs or gastric cancers. The pathogenic mechanisms explaining why limited subgroups of the patients develop these diseases are not understood. The differences in seroprevalence, disease spectrum and clinical outcome of this infection among the population with various ethnic background has been reported in Asian countries, which cannot be explained solely by genetical differences of the pathogen infected or by thedifferences in the socioeconomic as well as social sanitation levels in these countries. The host related factors should also determine clinical outcome of the infection, which are mostly unknown. In order to accumulate cl … More inical data and to study mechanisms of pathogenesis, we have established collaboration among investigators in Japan and abroad. We have obtained several findings out ofstudies utilizing human clinical samples and animal disease models.1, Not only the inflammatory mediators produced by the interaction between H.pylori and gastric epithelia, the host mucosal immune system including salivary glands and GALT (gut associated lymphoid tissue) also play important roles for the histological manifestation of the gastritis.2, We found differences in seroprevalence and profiles of antibodies to H.pylori in the blood among different ethnic groups in Malaysia and Japanese. This may explain different rate of incidence of gastric cancer and differences in clinical manifestation of the infection among study groups.3. Collaboration with investigators in Czech was carried out. Multiple parametric analyses in the patients with H.pylori infection in Czech revealed correlation among presence of H.pylori infection, family history of gastric cancer, level of ammonia produced in the stomach and grade of histological gastritis. Less

全球人口众多，超过二十亿，日本超过六千万人感染幽门螺杆菌（H.pylori）。还投入巨额资金用于治疗和预防与幽门螺杆菌感染相关的疾病。并非所有感染这种病毒的患者都会患上消化性溃疡、马尔托马病或胃癌等疾病。解释为什么有限的患者亚群患上这些疾病的致病机制尚不清楚。亚洲国家不同种族背景人群中该感染的血清流行率、疾病谱和临床结果存在差异，这不能仅仅用感染病原体的遗传差异或这些国家社会经济和社会卫生水平的差异来解释。宿主相关因素也应该决定感染的临床结果，而这些结果大多是未知的。为了积累临床数据并研究发病机制，我们在日本和国外的研究人员之间建立了合作。我们利用人类临床样本和动物疾病模型进行研究，获得了一些结果。1、不仅幽门螺杆菌与胃上皮细胞相互作用产生的炎症介质，包括唾液腺和GALT（肠道相关淋巴组织）在内的宿主粘膜免疫系统也在胃炎的组织学表现中发挥着重要作用。2、我们发现血清阳性率存在差异 以及马来西亚和日本不同种族人群血液中幽门螺杆菌抗体的概况。这可以解释不同研究组之间胃癌发病率的不同以及感染临床表现的差异。3．与捷克调查人员进行了合作。对捷克幽门螺杆菌感染患者进行的多参数分析揭示了幽门螺杆菌感染的存在、胃癌家族史、胃中产生的氨水平和组织学胃炎分级之间的相关性。较少的

项目成果

Suganuma M, et al.: "Helicobacter pylori membrane protein 1: a new carcinogenic factor of helicobacter pylori"Cancer Res. Sep1 61(17). 6356-6359 (2001)

Suganuma M等：“幽门螺杆菌膜蛋白1：幽门螺杆菌的新致癌因子”Cancer Res。

Tomohiro W, et al: "Oral administration of an antigen at a high dose generates tolerogenic CD4+CD25+T cells expressing CD95 ligand in the liver"J Immunol. 168. 2188-2199 (2002)

Tomohiro W 等人：“口服高剂量的抗原会在肝脏中产生表达 CD95 配体的耐受性 CD4 CD25 T 细胞”。

Tomohiro W, et al.: "Oral administration of an antigen at a high dose generates tolerogenic CD4+CD25+T cells expressing CD95 ligand in the liver"J Immunol. 168. 2188-2199 (2002)

Tomohiro W 等人：“口服高剂量的抗原会在肝脏中产生表达 CD95 配体的耐受性 CD4 CD25 T 细胞”。

Sakata-Kaneko,Y.Wakatsuki et al.: "Altered Th1/Th2 Commitment in Human CD4 T cells With Ageing."Clin Exp Immunology. 120. 267-273 (2000)

Sakata-Kaneko,Y.Wakatsuki 等人：“人类 CD4 T 细胞随着衰老而改变 Th1/Th2 承诺。”Clin Exp 免疫学。

Tomohiro W. et al.: "Oral administration of antigen at a high dose generates golerogenic CD+4+CD25+T cells expressing CD95 ligand in the liver"J Immunol. 168. 2188-2199 (2002)

Tomohiro W. 等人：“口服高剂量抗原会在肝脏中产生表达 CD95 配体的致胆固醇性 CD 4 CD25 T 细胞”。